Tissue-resident Immune Cell Subsets in aGVHD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorNanfang Hospital, Southern Medical University
About this trial
This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).
Eligibility criteria
Qualifiers
Voluntarily sign the informed consent form;
Age 16-65 years old
Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.
Disqualifiers
Have a history of other tumors
With poor compliance or mental disorders
Infected with HIV and HCV
With uncontrolled HBV infection
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov